GT Molecular
GT Molecular is a Fort Collins, Colorado-based molecular diagnostics company developing ultra-sensitive digital PCR, qPCR, and NGS assay kits and testing services for wastewater surveillance, oncology research, and pathogen detection, serving municipalities, academic labs, pharma, and forensic labs globally.
- Company typePrivate
- Founded2018
- HeadquartersFort Collins, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What GT Molecular does
GT Molecular is a Fort Collins, Colorado-based molecular diagnostics company, founded around 2018, that designs and commercializes ultra-sensitive digital PCR (dPCR), quantitative PCR (RT-qPCR), and next-generation sequencing (NGS) assay kits along with fee-for-service laboratory testing. Its core technology is the proprietary GT-Plex™ multiplexed PCR chemistry, described as patented or patent-pending, which the company markets as capable of detecting as few as 1–3 nucleic acid fragments per reaction. The company serves a diverse customer base that includes municipal and public-health wastewater surveillance programs, academic and clinical research laboratories, pharmaceutical and biotechnology companies, and forensic laboratories; it reaches these customers through a combination of direct sales, an e-commerce storefront, custom assay development services, and validated multi-pathogen assay panels delivered under federal contracts.
The company has built its commercial footprint primarily in wastewater-based pathogen surveillance, where it holds multi-year contracts with the CDC's National Wastewater Surveillance System covering dozens of assays, and has extended its product line into adjacent verticals including oncology research (EGFR and KRAS mutation panels), PFAS testing, arbovirus detection, and microbial-influenced-corrosion assays. A defining element of its go-to-market is platform-agnostic compatibility: GT Molecular offers kits validated on the four leading commercial dPCR platforms — Bio-Rad (QX200/QX600), QIAGEN (QIAcuity), Roche (Digital LightCycler), and Applied Biosystems/Thermo Fisher (QuantStudio Absolute Q) — enabling procurement by laboratories already invested in any major system. Revenue mechanics span federal contract awards (multi-year CDC task orders), catalog and custom kit sales, and contract laboratory testing services; the company is privately held with a headcount in the 11–50 range, and no public revenue or funding totals are disclosed in the available material.
GT Molecular firmographics
Firmographics- Name
- GT Molecular
- Legal name
- GT Molecular, Inc.
- Website
- https://gtmolecular.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- GT Molecular is a Fort Collins, Colorado-based molecular diagnostics company developing ultra-sensitive digital PCR, qPCR, and NGS assay kits and testing services for wastewater surveillance, oncology research, and pathogen detection, serving municipalities, academic labs, pharma, and forensic labs globally.
- Ownership category
- akta.pro rank
GT Molecular industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Wastewater & Environmental Pathogen Surveillance (HLAJABAI)
- akta.pro secondary industries
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI)
Keywords
Where GT Molecular is headquartered
LocationHeadquarters
- HQ city
- Fort Collins
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
GT Molecular business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- PCR Assay Kit Sales: GT Molecular sells commercial PCR assay kits (digital PCR and RT-qPCR formats) for wastewater surveillance, cancer research, and pathogen detection. Kits include primers, probes, and precisely measured positive and negative controls. Products are sold through an e-commerce storefront and are compatible with multiple instrument platforms (Bio-Rad, QIAGEN, Roche, Applied Biosystems). The company also offers custom assay development services for bespoke targets.
- Fee-for-Service Laboratory Testing: GT Molecular provides end-to-end wastewater testing services where customers purchase testing that includes sample collection kits, prepaid overnight return shipping, laboratory processing (extraction, dPCR/qPCR/NGS), and comprehensive data reporting. Results are delivered within 24-48 hours after sample receipt. Service covers pathogens (SARS-CoV-2, Influenza, RSV, mpox, norovirus, etc.), PFAS, opioids, and microbial source tracking.
- Custom Assay Development: GT Molecular offers custom dPCR and qPCR assay development services, leveraging patented molecular detection technology and standards to design assays for any target on virtually any PCR platform, providing a tailored solution for unique research or surveillance needs.
- Custom NGS Assay Development: Custom next-generation sequencing assay development services leveraging GT Molecular's design experience to customize, validate, and perform virtually any NGS assay.
- Custom Mass Spectrometry Assay Development: Custom mass spectrometry assay development services for detecting minute amounts of targets of interest with customized, validated mass spectrometry assays.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | PCR assay kits are sold in standard reaction sizes (typically 200 reactions per kit) with pricing determined by product type and platform compatibility. |
| Other | Pay-as-you-go | Fee-for-service wastewater testing includes sample collection kit, prepaid overnight return shipping, and comprehensive report generation. |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
GT Molecular product offering
Product offeringCore offering
GT Molecular designs, manufactures, and sells digital PCR, qPCR, and next-generation sequencing (NGS) assay kits for wastewater-based pathogen surveillance and cancer mutation detection, and operates a fee-for-service laboratory offering testing for SARS-CoV-2, influenza, RSV, H5/H5N1, mpox, measles, norovirus, opioids, PFAS, and microbial source tracking. The company also provides custom assay development across dPCR, qPCR, NGS, and mass spectrometry platforms, and offers sequencing and RNA extraction services from wastewater samples.
Product overview
GT Molecular offers a portfolio of molecular diagnostic products organized into assay kits, testing services, and custom assay development. Its core product lines are built around the patented GT-Plex™ technology for multiplexed digital PCR (dPCR) and real-time qPCR assays. Assay kits are available across four major dPCR/qPCR instrument platforms: Bio-Rad QX200™/QX600™, QIAGEN QIAcuity®, Applied Biosystems QuantStudio™ Absolute Q™, and Roche Digital LightCycler®, as well as RT-PCR platforms. Key product families include: (1) Wastewater surveillance assay kits for SARS-CoV-2, influenza A/B, RSV, H5, mpox, pertussis, EV-D68, and hepatitis A; (2) Respiratory multiplex panels combining Flu/SC2/RSV/BCoV targets; (3) Cancer research panels (GT-Plex™) for ESR1, EGFR, and KRAS mutations; (4) Microbial Source Tracking (MST) panels and individual assays for human, animal, and bird fecal contamination markers; (5) The GT-Fast Prep Influenza A Library Kit for Illumina NGS; and (6) A full suite of fee-for-service wastewater testing services (SARS-CoV-2, flu, RSV, mpox, H5, measles, C. auris, norovirus, HMPV, opioids, PFAS, microbial source tracking, 16S sequencing, and custom NGS) offered from GT Molecular's national laboratory. The company also provides custom assay development services for dPCR, qPCR, NGS, and mass spectrometry. GT Molecular's testing services customers receive data within 24 to 48 hours after sample receipt, and assay kits are validated for use with extraction workflows from Promega, CERES Nanotrap, and Thermo Fisher Scientific.
Differentiator
Problem solved
Functional benefit
Brands
- GT-Plex™: Patented and patent-pending technology for highly multiplexed digital PCR and qPCR assays providing ultrasensitive detection for cancer research and pathogen detection
- GT-Digital™
- GT-Fast Prep
- GT Real-Time
Products and services
- GT-Digital™ Flu;SC2;RSV;BRSV Wastewater Surveillance Panel v1.0 (Bio-Rad QX600) Multiplex digital PCR assay kit detecting influenza, SARS-CoV-2, RSV, and BRSV in wastewater samples, validated for the Bio-Rad QX600 dPCR platform and intended for public health surveillance laboratories.
- GT-Digital™ Flu;SC2;RSV;BCoV Wastewater Surveillance Panel v1.0 (QIAcuity) Multiplex digital PCR assay kit detecting influenza, SARS-CoV-2, RSV, and bovine coronavirus in wastewater samples, validated for the QIAGEN QIAcuity platform.
- GT-Digital™ Flu;SC2;RSV Wastewater Surveillance Panel v1.0 (QuantStudio Absolute Q) Multiplex digital PCR assay kit for influenza, SARS-CoV-2, and RSV in wastewater, validated for the Applied Biosystems QuantStudio Absolute Q dPCR platform.
- Roche Digital LightCycler® Respiratory Panel Digital PCR respiratory pathogen assay kit validated for the Roche Digital LightCycler instrument platform.
- GT-Plex™ ESR1 Mutation Panel Digital PCR assay panel for detecting ESR1 gene mutations in cancer research and liquid biopsy applications, used by oncology research and translational laboratories.
- GT-Plex™ EGFR Mutation Panels Digital PCR assay panels for detection of EGFR mutations in cancer research and clinical research applications, marketed to oncology research laboratories.
- GT-Plex™ KRAS Mutation Panels Digital PCR assay panels for detecting KRAS mutations in cancer research samples, targeted at oncology translational and clinical research laboratories.
- GT-Digital™ HepA ROX Add-On Wastewater Surveillance Assay v1.0 (Bio-Rad QX600) ROX-channel digital PCR add-on assay for detecting hepatitis A in wastewater, designed to run alongside other GT-Digital assays on the Bio-Rad QX600 instrument.
- GT-Digital™ HepA Wastewater Surveillance Assay v1.0 (QIAcuity) Digital PCR assay kit for hepatitis A detection in wastewater samples, validated for the QIAGEN QIAcuity platform.
- GT-Digital™ Bordetella pertussis Wastewater Surveillance Assay Kit v1.0 (QIAcuity) Digital PCR assay kit for detecting Bordetella pertussis in wastewater, validated for the QIAGEN QIAcuity platform and used in public-health surveillance of whooping cough.
- GT-Digital™ Bordetella pertussis Wastewater Surveillance Assay Kit v1.0 (Bio-Rad QX200/QX600) Digital PCR assay kit for detecting Bordetella pertussis in wastewater, validated for Bio-Rad QX200 and QX600 dPCR instruments.
- GT-Digital™ EV-D68 Wastewater Surveillance Panel v1.0 (QIAcuity) Digital PCR assay panel for detecting enterovirus D68 in wastewater samples, validated for the QIAGEN QIAcuity platform.
- GT-Digital H5* Wastewater Surveillance Assay v1.0 (QIAcuity) Digital PCR assay kit for detecting H5-subtype avian influenza in wastewater, validated for the QIAGEN QIAcuity platform and intended for avian-flu surveillance programs.
- GT-Digital™ Microbial Source Tracking Human;E.coli;Cow;Gull;Dog Panel v1.0 (QIAGEN QIAcuity) Multiplex digital PCR microbial source tracking assay differentiating human, E. coli, cow, gull, and dog fecal contributions in water samples, validated for QIAGEN QIAcuity.
- GT-Digital™ RSV Wastewater Surveillance Assay Kit (QIAGEN QIAcuity) Digital PCR assay kit for detecting respiratory syncytial virus (RSV) in wastewater samples, validated for the QIAGEN QIAcuity platform.
- GT-Digital™ Influenza and SARS-CoV-2 Wastewater Surveillance Multiplex Assay Kit (QIAcuity) Multiplex digital PCR assay kit for simultaneous detection of influenza and SARS-CoV-2 in wastewater, validated for the QIAGEN QIAcuity platform.
- GT Quantitative Real-Time Flu;SC2;RSV;BCoV Wastewater Surveillance Assay v1.0 Quantitative real-time (qPCR) multiplex assay for influenza, SARS-CoV-2, RSV, and bovine coronavirus in wastewater samples.
- GT Real-Time PCR SARS-CoV-2, Flu A/B and RSV Assay Kit Real-time PCR multiplex assay for SARS-CoV-2, influenza A/B, and RSV, applicable to clinical and wastewater surveillance workflows.
- GT Real-Time MST Inland Detection Panel v1.0 Real-time PCR microbial source tracking panel configured for inland water applications.
- GT Real-Time MST Beach Detection Panel v1.0 Real-time PCR microbial source tracking panel configured for coastal/beach water applications.
- GT-Fast Prep Influenza A Library Kit for Illumina Next-generation sequencing library preparation kit for influenza A, optimized for Illumina sequencing platforms and used in viral surveillance and wastewater sequencing workflows.
- SARS-CoV-2 + Multi-Variant Wastewater Test Laboratory service testing wastewater samples for SARS-CoV-2 and identifying multiple variants, provided as a turnkey fee-for-service test to public-health and surveillance clients.
- SARS-CoV-2 + Pan-Omicron Variant Panel Wastewater Testing Service Laboratory wastewater testing service that screens for SARS-CoV-2 and characterizes Omicron-lineage variants in submitted wastewater samples.
- SARS-CoV-2 Single Test Wastewater Testing Service Fee-for-service single-target wastewater test detecting SARS-CoV-2 in submitted wastewater samples.
- Influenza A/B Wastewater Testing Service Fee-for-service wastewater test detecting influenza A and B in submitted wastewater samples.
- Mpox Wastewater Single Test Fee-for-service wastewater test detecting mpox virus in submitted wastewater samples.
- RSV Wastewater Single Test Fee-for-service wastewater test detecting RSV in submitted wastewater samples.
- Respiratory Panel Wastewater Test Fee-for-service wastewater multiplex test covering the respiratory pathogen panel (SARS-CoV-2, influenza, RSV, etc.) in submitted wastewater samples.
- Respiratory Panel Wastewater Test (qPCR) qPCR-based version of the respiratory panel wastewater test service for submitted wastewater samples.
- Measles Wastewater Testing Service Fee-for-service wastewater test detecting measles virus in submitted wastewater samples.
- C. auris Wastewater Testing Service Fee-for-service wastewater test detecting Candida auris in submitted wastewater samples.
- Norovirus GI;GII Wastewater Testing Service Fee-for-service wastewater test detecting norovirus genogroups GI and GII in submitted wastewater samples.
- HMPV Wastewater Testing Service Fee-for-service wastewater test detecting human metapneumovirus (HMPV) in submitted wastewater samples.
- Microbial Source Tracking Testing Service Fee-for-service laboratory test profiling microbial source tracking markers in submitted water or wastewater samples.
- Opioid Testing Service for Wastewater Sample (1-5 Targets) Fee-for-service wastewater test screening for 1 to 5 opioid-related analytes in submitted wastewater samples.
- Opioid Testing Service for Wastewater Sample (6+ Targets) Fee-for-service wastewater test screening for 6 or more opioid-related analytes in submitted wastewater samples.
- PFAS Testing Service: EPA Method 533 Fee-for-service PFAS testing in submitted samples following U.S. EPA Method 533, targeted at environmental and municipal water laboratories.
- PFAS Testing Service: EPA Method 1633A Fee-for-service PFAS testing in submitted samples following U.S. EPA Method 1633A, intended for environmental and municipal water testing programs.
- Influenza H5 Milk Testing Service Fee-for-service laboratory test detecting H5-subtype avian influenza in submitted raw-milk samples for dairy surveillance programs.
- Extracted RNA from Wastewater Fee-for-service RNA extraction from submitted wastewater samples, delivering extracted RNA suitable for downstream PCR or sequencing workflows.
- 16S Sequencing of Wastewater for Microbial Community Analysis Fee-for-service 16S rRNA sequencing of wastewater samples for microbial community analysis, providing taxonomic profiling of wastewater microbiomes.
- SARS-CoV-2 Sequencing Service for Wastewater Fee-for-service SARS-CoV-2 sequencing performed on submitted wastewater samples for variant identification and surveillance.
- Flu A Sequencing Service Add-on for Wastewater Add-on sequencing service for influenza A from submitted wastewater samples, used in conjunction with wastewater surveillance testing.
- Custom dPCR and qPCR Assays and Standards Custom development service for digital PCR and quantitative PCR assays and reference standards, tailored to customer-specified targets for research and surveillance applications.
- Custom NGS Assays Custom next-generation sequencing assay development service, building targeted NGS assays against customer-specified genomic targets.
- Custom Mass Spectrometry Assays
Quantifiable outcome
- Detection of as few as 1-3 nucleic acid fragments in wastewater samples
- +5 more outcomes
Companies that use GT Molecular
Customer profileNamed customers1 record
Segments7 records
Ideal customer profiles4 records
GT Molecular technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration7 records
Feature9 records
GT Molecular partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and flagship.
- Applied Biosystems (Thermo Fisher Scientific)coreGT Molecular introduced four new assay kits for the Applied Biosystems™ QuantStudio™ Absolute Q™ Digital PCR System, bringing its deep experience in dPCR and ultra-sensitive patented assay kits to the Absolute Q platform. New products include ESR1 mutation panel, Flu;SC2;RSV panel, BCR-ABL Fusion Detection Panel, and NPM1 Insertion Detection Assay.
- Centers for Disease Control and Prevention (CDC) — NWSS Multi-Pathogen ContractflagshipGT Molecular was awarded the CDC NWSS Multi-Pathogen Assay Development Optimization, Validation, and Support contract. This work builds on previously successful CDC contracts and incorporates emerging public health threat targets from viral, bacterial, parasitic, fungal, AMR, infectious disease source tracking, and disease vector categories. The project spans up to five years (12-month base + four 12-month options) with contract value up to approximately $1.7 million. GT Molecular will develop up to 30 multi-pathogen dPCR assays for validation testing at the CDC and up to five public health partner laboratories.
- Roche (Diagnostics)coreGT Molecular entered into an agreement with Roche to provide a highly multiplexed respiratory panel for wastewater surveillance on the Roche Digital LightCycler® System. This digital PCR assay kit co-quantifies respiratory pathogens SARS-CoV-2, influenza A, influenza B, and RSV. The partnership enables GT Molecular to offer its assays on a fourth major platform alongside Bio-Rad, QIAGEN, and Applied Biosystems.
- Centers for Disease Control and Prevention (CDC)flagshipCDC's National Wastewater Surveillance System (NWSS) is collaborating with GT Molecular to create digital PCR assays and multiplex dPCR panels for national wastewater surveillance. The goal is to make assays available as methods and kits to public health lab partners. Targets include gastrointestinal, respiratory, and antimicrobial resistant pathogens through approximately 24 digital PCR wastewater surveillance targets. GT Molecular was previously awarded a 2023 contract (~$1.7M over 5 years) for developing 28 assays on Bio-Rad QX and Qiagen QIAcuity instruments, and in September 2024 was awarded a further multi-pathogen assay development contract.
- Bio-Rad LaboratoriescoreBio-Rad and GT Molecular announced a joint whitepaper on hMPXV (human monkeypox) surveillance and testing for wastewater-based epidemiology. GT Molecular's ddPCR™ PCR kits for WBE were demonstrated as capable and effective tools for SARS-CoV-2 outbreak monitoring and mpox detection. GT Molecular develops multiplexed assays for Bio-Rad's QX200™ and QX600™ Droplet Digital™ PCR Systems, including respiratory panels, H5 avian flu, pertussis, hepatitis A, microbial source tracking panels, and oncology panels.
- QIAGENcoreGT Molecular collaborated with QIAGEN to offer a complete SARS-CoV-2 wastewater detection solution based on the QIAcuity Digital PCR technology. GT Molecular's digital SARS-CoV-2 Wastewater Surveillance Assay was developed to comply with CDC guidelines for the US National Wastewater Surveillance System (NWSS). The workflow leverages QIAGEN's sample-preparation expertise and the QIAcuity instrument platform. GT Molecular has since expanded its assay catalog for the QIAcuity platform, including multiplex respiratory panels, H5 avian flu assays, EV-D68, pertussis, hepatitis A, and microbial source tracking panels.
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
GT Molecular competitors and assessment
Company assessmentBroad incumbents
- QIAGEN: QIAGEN manufactures the QIAcuity Digital PCR System that GT Molecular validates assays against and has a co-development partnership with. Comparable because QIAGEN is both an instrument partner and a competitor offering its own sample-to-result molecular diagnostic workflows including wastewater surveillance assays.
- Eurofins Scientific: Eurofins operates one of the largest global networks of clinical and environmental testing laboratories, including PFAS, pathogen, and wastewater testing services. Comparable as a broad incumbent offering outsourced laboratory services across many of the same analyte categories as GT Molecular's testing services.
- Roche Diagnostics: Roche Diagnostics manufactures the Digital LightCycler dPCR system for which GT Molecular developed a respiratory wastewater panel under commercial agreement. Comparable as a large diagnostics incumbent that is simultaneously a platform partner and a competitor in molecular diagnostics broadly.
- Bio-Rad Laboratories: Bio-Rad manufactures the QX200/QX600 Droplet Digital PCR systems on which GT Molecular's assays run, and also develops its own ddPCR oncology and infectious disease assays. Comparable because Bio-Rad is both a platform partner and a direct assay competitor in the same dPCR-based molecular diagnostics space.
- IDEXX Laboratories: IDEXX provides water microbiology testing products and services for municipal water utilities, including microbial source tracking and waterborne pathogen detection. Comparable because it overlaps with GT Molecular's microbial source tracking and water-quality testing segments serving utilities and municipalities.
- Thermo Fisher Scientific: Thermo Fisher manufactures the QuantStudio Absolute Q Digital PCR System for which GT Molecular launched four new assay kits in May 2025, plus the MagMAX Wastewater Ultra extraction kit. Comparable as a broad life sciences incumbent that is both a platform/extraction partner and a competitor across molecular diagnostics.
Direct peers
- Streck: Streck provides molecular diagnostics QC, sample collection/stabilization products, and molecular testing services including wastewater surveillance. Comparable as a smaller specialty competitor serving public health and clinical labs with both consumables and testing services.
- Biobot Analytics: Biobot Analytics is a leading wastewater-based epidemiology company providing SARS-CoV-2, influenza, RSV, and opioid surveillance services to municipalities across the US. Comparable as the most direct competitor in wastewater pathogen surveillance services, with overlapping customers (municipalities, public health departments) and similar fee-for-service testing model.
- Ceres Nanosciences: Ceres Nanosciences develops Nanotrap particle-based sample concentration workflows for wastewater pathogen detection, which GT Molecular integrates with its dPCR assays. Comparable because both companies serve the wastewater surveillance workflow with complementary technologies, and both target public health laboratories.
- LuminUltra: LuminUltra provides microbial monitoring and wastewater surveillance testing services and qPCR-based kits for water utilities and public health agencies. Comparable as a direct competitor offering end-to-end wastewater surveillance solutions, with overlapping technology (qPCR) and customer base (water utilities, municipalities).
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
GT Molecular social profiles
Digital presenceGT Molecular financial estimates
Financial estimateRevenue estimate
Valuation estimate
GT Molecular leadership team
Management profileNumber of profiles
GT Molecular funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GT Molecular M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GT Molecular
What does GT Molecular do?
GT Molecular designs, manufactures, and sells digital PCR, qPCR, and next-generation sequencing (NGS) assay kits for wastewater-based pathogen surveillance and cancer mutation detection, and operates a fee-for-service laboratory offering testing for SARS-CoV-2, influenza, RSV, H5/H5N1, mpox, measles, norovirus, opioids, PFAS, and microbial source tracking. The company also provides custom assay development across dPCR, qPCR, NGS, and mass spectrometry platforms, and offers sequencing and RNA extraction services from wastewater samples.
Is GT Molecular a public or private company?
GT Molecular is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was GT Molecular founded?
GT Molecular was founded in 2018. It employs 11 to 50 people.
Where is GT Molecular based?
GT Molecular is headquartered in Fort Collins, United States, in the North America region.
How does GT Molecular make money?
Five revenue lines are on record. PCR Assay Kit Sales are the primary driver. The others are fee-for-Service Laboratory Testing, custom Assay Development, custom NGS Assay Development and custom Mass Spectrometry Assay Development.
Who are GT Molecular's main competitors?
Broad incumbents on record are QIAGEN, Eurofins Scientific, Roche Diagnostics, Bio-Rad Laboratories, IDEXX Laboratories and Thermo Fisher Scientific. Direct peers are Streck, Biobot Analytics, Ceres Nanosciences and LuminUltra.
Does GT Molecular have an API?
No public API is recorded for GT Molecular.
What industry is GT Molecular in?
GT Molecular's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAJABAI, Wastewater & Environmental Pathogen Surveillance, with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 325413 and its SIC code is 2835.